STOCK TITAN

[SCHEDULE 13G/A] Merck & Co., Inc. Amended Passive Investment Disclosure

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting 0 shares of Merck & Co., Inc. common stock. The amendment states that, following an internal realignment on January 12, 2026, certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership in MRK after internal disaggregation.

The filing disaggregates ownership following an internal realignment dated January 12, 2026, and states that certain subsidiaries or business divisions will report separately per SEC Release No. 34-39538. The amendment records 0 shares and 0% beneficial ownership.

This is an administrative disclosure about reporting structure rather than an economic trade; cash‑flow treatment and any subsidiary-level holdings are not stated in the excerpt. Subsequent subsidiary filings could show active positions.






58933Y105

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026
Merck & Co

NYSE:MRK

View MRK Stock Overview

MRK Rankings

MRK Latest News

MRK Latest SEC Filings

MRK Stock Data

294.04B
2.47B
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
RAHWAY